PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 63, Issue 4, Pages 395-406
Publisher
Springer Nature
Online
2014-02-10
DOI
10.1007/s00262-014-1519-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
- (2013) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
- (2012) M. S. N. Mohd Sharial et al. ANNALS OF ONCOLOGY
- Characterisation of tumour-infiltrating macrophages: impact on response and survival in patients receiving primary chemotherapy for breast cancer
- (2012) Steven D. Heys et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer
- (2012) N R West et al. BRITISH JOURNAL OF CANCER
- Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer
- (2012) Hui Liu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
- (2012) Esdy N. Rozali et al. Clinical & Developmental Immunology
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer
- (2012) F. Andre et al. CLINICAL CANCER RESEARCH
- The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature
- (2012) R. J. deLeeuw et al. CLINICAL CANCER RESEARCH
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Immunotherapy earns its spot in the ranks of cancer therapy
- (2012) Drew Pardoll et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Clinical opportunities and challenges in targeting tumour dormancy
- (2012) Jonathan A. Hensel et al. Nature Reviews Clinical Oncology
- PD1 makes waves in anticancer immunotherapy
- (2012) Alexandra Flemming NATURE REVIEWS DRUG DISCOVERY
- Tumor Immunotherapy Directed at PD-1
- (2012) Antoni Ribas NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Programmed Death 1 Expression as a Marker for Immune and Physiological Dysfunction in the Critically Ill Surgical Patient
- (2012) Sean F. Monaghan et al. SHOCK
- CD8+T lymphocytes infiltrating breast cancer
- (2012) Sahar Mahmoud et al. OncoImmunology
- Targeting PD-1/PD-L1 interactions for cancer immunotherapy
- (2012) Laurence Zitvogel et al. OncoImmunology
- CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes
- (2011) Fangfang Liu et al. BREAST CANCER RESEARCH AND TREATMENT
- Improving cancer immunotherapy by targeting tumor-induced immune suppression
- (2011) Trina J. Stewart et al. CANCER AND METASTASIS REVIEWS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Therapeutic targeting of B7-H1 in breast cancer
- (2011) Amal Hasan et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Tumor-induced changes in the phenotype of blood-derived and tumor-associated T cells of early stage breast cancer patients
- (2011) I. Poschke et al. INTERNATIONAL JOURNAL OF CANCER
- Tumor Evasion from T Cell Surveillance
- (2011) Katrin Töpfer et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Cancer Immunotherapy Comes of Age
- (2011) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
- (2011) Sahar M.A. Mahmoud et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Early T Cell Signalling Is Reversibly Altered in PD-1+ T Lymphocytes Infiltrating Human Tumors
- (2011) Shu-Fang Wang et al. PLoS One
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia
- (2010) Q. Zhou et al. BLOOD
- An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer
- (2010) Sahar M. A. Mahmoud et al. BREAST CANCER RESEARCH AND TREATMENT
- PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
- (2010) Feng Shi et al. INTERNATIONAL JOURNAL OF CANCER
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- FOXP3+ Tregs and B7-H1+/PD-1+T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy
- (2008) Hazem Ghebeh et al. BMC CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More